The RNA Polymerase “Switch Region” Is a Target for Inhibitors

Howard Hughes Medical Institute, Rutgers University, Piscataway, NJ 08854, USA.
Cell (Impact Factor: 33.12). 11/2008; 135(2):295-307. DOI: 10.1016/j.cell.2008.09.033
Source: PubMed

ABSTRACT The alpha-pyrone antibiotic myxopyronin (Myx) inhibits bacterial RNA polymerase (RNAP). Here, through a combination of genetic, biochemical, and structural approaches, we show that Myx interacts with the RNAP "switch region"--the hinge that mediates opening and closing of the RNAP active center cleft--to prevent interaction of RNAP with promoter DNA. We define the contacts between Myx and RNAP and the effects of Myx on RNAP conformation and propose that Myx functions by interfering with opening of the RNAP active-center cleft during transcription initiation. We further show that the structurally related alpha-pyrone antibiotic corallopyronin (Cor) and the structurally unrelated macrocyclic-lactone antibiotic ripostatin (Rip) function analogously to Myx. The RNAP switch region is distant from targets of previously characterized RNAP inhibitors, and, correspondingly, Myx, Cor, and Rip do not exhibit crossresistance with previously characterized RNAP inhibitors. The RNAP switch region is an attractive target for identification of new broad-spectrum antibacterial therapeutic agents.

Download full-text


Available from: Kalyan Das, Jun 17, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Covering: up to the end of 2013Myxobacteria produce a vast range of structurally diverse natural products with prominent biological activities. Here, we provide a detailed description and judge the potential of all antibiotically active myxobacterial compounds as lead structures, pointing out their particularities and, if known, their mode of action. Thus, the review provides an overview of the potential of specific compounds, suitable for future investigations and possible clinical applications.
    Natural Product Reports 05/2014; DOI:10.1039/c4np00011k · 10.72 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: After the introduction of isoniazid and rifampicin, the second one discovered in the Lepetit Research Laboratories (Milan, Italy), under the supervision of Professor Piero Sensi, tuberculosis (TB) was considered an illness of the past. Unfortunately, this infectious disease is still a global health fear, due to the multidrug-resistant Mycobacterium tuberculosis and extensively circulating drug-resistant strains, as well as the unrecognized TB transmission, especially in regions with high HIV incidence. In the last few years, new antitubercular molecules appeared on the horizon both in preclinical and clinical stage of evaluation. In this review, we focus on a few of them and on their mechanism of action. Two new promising drug targets, DprE1 and MmpL3, are also discussed.The Journal of Antibiotics advance online publication, 6 August 2014; doi:10.1038/ja.2014.109.
    The Journal of Antibiotics 08/2014; DOI:10.1038/ja.2014.109 · 2.04 Impact Factor
  • Source